🇮🇳 India Stock Screener ← Switch market ⚡ HerAI

Gujarat Kidney And Super Speciality Limited GKSL NSEPHARMA

Healthcare · Medical Care Facilities · India
https://www.gujaratsuperspecialityhospital.com
Company Profile ↓
₹179.46
+71.67% 1Y
Mkt Cap₹1,414.92 Cr
P/E70.65
P/B4.54
52W High₹194.69
52W Low₹99.36
Book Value₹40.57
EPS (TTM)₹2.54

Company Overview

Gujarat Kidney and Super Speciality Limited operates multi-specialty and super-specialty hospitals in India. It provides treatment for Oncology, Neurology, Gastroenterology, Urology, Nephrology, and Physiotherapy. It also offers Renal Surgery, Vascular Surgery, Gynecology and obstetrics, Robotic Surgery, Bariatric Surgery, Laparoscopic Surgery, Endocrine Surgery, Neurosurgery, and Joint Replacement services. Its facilities include intensive care unit, rooms, patient counselling, operation theatres, and dialysis center. Gujarat Kidney And Super Speciality Limited was founded in 2014 and is headquartered in Vadodara, India.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 32.7% per year over the last five years.

Healthy Margins

Maintains a net profit margin of 15.7%.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.11.

Recent Developments

  • Mar 2026 Revenue of ₹82.01 Cr (+103.8% YoY); net profit ₹15.50 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +124.7%, earnings -22.4%.
  • 5-Year Trend Long-term compounding — revenue CAGR -1.5%, profit CAGR 32.7%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-1.49%
1 Year:124.70%

Compounded Profit Growth

5 Years:32.67%
1 Year:-22.40%

Stock Price Performance

1 Year:+71.67%
6 Months:+55.46%
3 Months:+40.97%
1 Month:+2.45%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 84% of range
₹99.36 ₹194.69
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)48.45 · Neutral
Price Performance
1M+2.45%
3M+40.97%
6M+55.46%
1Y+71.67%
Valuation vs Sector

P/E of 70.65 is above the sector median of 35.90 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Profit CAGR of 32.7% over 5 years.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading at a high P/E of 70.7.
  • Revenue declined at -1.5% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
70.65
Industry PE
35.90
Forward P/E est.
91.04
PEG Ratio
-
Book Value
₹40.57
Price to Book
4.54
P/S
14.36
EV/EBITDA
54.00
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-1.49%
Profit 5Y
32.67%
Revenue (YoY)
124.70%
Earnings (YoY)
-22.40%

Profitability & Returns

ROCE
8.57%
ROE
6.14%
ROA
5.21%
Profit Margin
15.67%
Op Margin
20.24%
Gross Margin
71.39%
EPS (Latest Qtr)
₹0.81
EPS (TTM)
₹2.54

Balance Sheet & Liquidity

Debt/Equity
0.11
Quick Ratio
3.69
Current Ratio
3.76
Debt
₹29.11 Cr
Total Assets
₹297.64 Cr
Current Assets
₹104.59 Cr
Working Capital
₹76.77 Cr

Ownership

Promoter Holding
74.79%
Chg in Prom Hold
-
FII / Inst Holding
0.00%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
₹1,414.92 Cr
Total Revenue (TTM)
₹101.04 Cr
EBITDA
₹26.61 Cr
Free Cash Flow
₹-157.28 Cr
Operating Cash Flow
₹-3.86 Cr
Shares Outstanding
₹7.88 Cr
Gross Margin
71.39%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 GKSL Gujarat Kidney And Super Speciality Limited NSEPHARMA 179.46 70.65 ₹1,414.92 Cr 0.00% 8.57% 6.14% -1.49% 32.67%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,758.00 34.88 ₹4.22 L Cr 0.91% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,162.00 83.32 ₹2.43 L Cr 0.32% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,615.30 73.73 ₹1.76 L Cr 0.81% 9.05% 25.79% 13.27% 20.22%
5 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,135.00 25.30 ₹1.13 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
6 LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA 634.25 165.17 ₹1.10 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 7,604.50 52.35 ₹1.09 L Cr 0.25% 19.20% 20.48% 14.85% 33.34%
8 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 2,002.50 98.99 ₹1.08 L Cr 0.12% 19.53% 16.77% 3.77% 4.00%
9 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,330.90 31.92 ₹1.08 L Cr 0.99% 14.86% 11.27% 7.23% 11.45%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 9.41 Cr11.79 Cr9.78 Cr31.09 Cr12.93 Cr23.25 Cr30.58 Cr
Cost of Revenue -1.03 Cr1.57 Cr3.25 Cr-3.05 Cr3.37 Cr
Gross Profit -10.76 Cr8.22 Cr27.84 Cr-20.19 Cr27.21 Cr
Operating Expenses 4.55 Cr7.04 Cr6.50 Cr15.87 Cr7.81 Cr14.63 Cr22.42 Cr
Operating Income 4.12 Cr3.71 Cr1.72 Cr11.97 Cr4.22 Cr5.56 Cr4.79 Cr
EBITDA 4.86 Cr4.65 Cr2.67 Cr13.66 Cr5.12 Cr6.96 Cr7.01 Cr
Interest Expense 16.00 L16.65 L16.41 L50.87 L28.00 L59.85 L81.80 L
Pretax Income 4.00 Cr3.60 Cr1.60 Cr11.52 Cr4.03 Cr5.03 Cr4.69 Cr
Tax Provision 1.05 Cr1.07 Cr27.13 L3.16 Cr1.15 Cr1.32 Cr-14.02 L
Net Income 2.96 Cr2.50 Cr1.28 Cr7.80 Cr2.88 Cr2.94 Cr5.04 Cr
Diluted EPS 18.390.320.160.990.470.520.81

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 85.79 Cr103.44 Cr40.24 Cr82.01 Cr
Cost of Revenue 9.79 Cr11.16 Cr3.96 Cr9.12 Cr
Gross Profit 76.01 Cr92.28 Cr36.28 Cr72.90 Cr
Operating Expenses 64.41 Cr77.54 Cr23.02 Cr50.66 Cr
Operating Income 11.60 Cr14.74 Cr13.26 Cr22.24 Cr
EBITDA 17.93 Cr22.03 Cr16.70 Cr27.81 Cr
Interest Expense 2.08 Cr2.35 Cr64.63 L1.88 Cr
Pretax Income 9.84 Cr13.57 Cr12.77 Cr21.23 Cr
Tax Provision 3.48 Cr3.60 Cr3.27 Cr4.42 Cr
Net Income 6.64 Cr9.68 Cr9.41 Cr15.50 Cr
Diluted EPS 0.841.231.192.49

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 63.86 Cr65.40 Cr91.29 Cr297.64 Cr
Current Assets 20.56 Cr24.82 Cr37.74 Cr104.59 Cr
Cash & Equivalents 1.90 Cr3.90 Cr4.58 Cr13.28 Cr
Inventory 68.50 L1.04 Cr1.45 Cr2.06 Cr
Receivables 13.66 Cr15.47 Cr25.06 Cr38.63 Cr
Total Liabilities 41.56 Cr42.55 Cr51.46 Cr42.90 Cr
Current Liabilities 22.54 Cr18.32 Cr32.77 Cr27.82 Cr
Long Term Debt 12.23 Cr9.10 Cr4.79 Cr1.79 Cr
Total Debt 23.20 Cr27.34 Cr22.77 Cr29.11 Cr
Total Equity 21.96 Cr22.27 Cr38.64 Cr252.51 Cr
Shares Outstanding 7.88 Cr7.88 Cr7.88 Cr7.88 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 1,0001.21 Cr13.61 Cr-3.86 Cr
Investing Cash Flow 022.33 L-18.14 Cr-213.85 Cr
Financing Cash Flow 0-46.93 L6.16 Cr228.40 Cr
Capital Expenditure ---18.25 Cr-153.42 Cr
Free Cash Flow 1,0001.21 Cr-4.64 Cr-157.28 Cr
Net Change in Cash 1,00096.68 L1.63 Cr10.69 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % 88.6%89.2%90.2%88.9%
Operating Margin % 13.5%14.3%32.9%27.1%
Net Margin % 7.7%9.4%23.4%18.9%
ROE % 30.2%43.5%24.4%6.1%
ROCE % 28.1%31.3%22.7%8.2%

Shareholding Pattern

Insiders
74.79%
Institutions
0.00%
Public Float
0.00%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for GKSL

Google News Mon, 19 Oct 2026

Price Performance - Yahoo! Finance Canada

<a href="https://news.google.com/rss/articles/CBMiV0FVX3lxTE5CaXZNVHZqZDVOTHdrWUY4U3p1Yno5MVRkNTFxNWVUZFFWWmlHdmhCSm5Hb0x0WUZaaFM4TEJUYjlIbkItQWVzWTZ4Z1ltQ2Jhdkh0VC1MTQ?oc=5" target="_blank">Price Performance</a>&nbsp;&nbsp;<font color="#6f…

Google News ue, 30 Dec 2025

GKSL Stock Price and Chart — NSE:GKSL - TradingView

<a href="https://news.google.com/rss/articles/CBMiWEFVX3lxTE9uT3h5dkZadUc1LW5Qd25LZmxKd3B6YkdhQlQtOHlVa3B6czVUMjhkS2drWjhLWV9UNUg4cFh4SWt2UmZLOUh5ZFdrTkdDdDc4aTNzUV9rRzk?oc=5" target="_blank">GKSL Stock Price and Chart — NSE:GKSL</a>&nbsp;&…

Google News Mon, 17 Aug 2026

GUJARAT KIDNEY N SUP SP L Share Price News and Analysis - Univest

<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxOUEZ2TXd1cjVqODkzNXY1bHd3STBxVWQyRmpSZzk4WURkMXU5MnNTUkhCT3V4YVM5eUlVUC1mWUp5OW1xV1NVNnRHLXpCOC1rRWFkcUZtODl0SGNzTmNnNWxuNUU4UkY4R011UFhOVFNYa3ZjT1NVWGZVMl9YTW84UTBsUDl1RXFxVVE?oc…

Google News Fri, 05 Jun 2026

Concerns Surrounding Gujarat Kidney And Super Speciality's (NSE:GKSL) Performance - Simply Wall Street

<a href="https://news.google.com/rss/articles/CBMi8gFBVV95cUxNWUp3b0V1aXdJTDhtRUo3V1pPRFRMRkNnQ1daMXBVVEV6Z3lJWkNpUm5tc1dDSFNvUW5XUDVZMmN1cEVxTmhxVEdkdnY4c0h2SVF5akNxbXpMVHk4ZHNRSjRoR2R2TXV0anNYbHBYSXB6TFJ3ZG0xSFRERDExV1FvbTVSSkxUaWtDNHZpYz…

Google News ue, 05 May 2026

GUJARAT KIDNEY N SUP SP L Share Price - Upstox

<a href="https://news.google.com/rss/articles/CBMickFVX3lxTE9USWJyM1hGTVAtWEJXUy1FZEFtRWRqd3RZUGYtMm50c0hCaU9YcWJwcTRmOV9wZnNpTWwyd012WHYtdTcwLUxNMmpyZFdLcUg0NlhoSnRxOXNzdlMzQ2RXRjU4UEVEMlBWVXhMLUczN29UZw?oc=5" target="_blank">GUJARAT KIDNE…

Google News hu, 14 May 2026

Gujarat Kidney & Super Speciality Ltd | Stock Share Price Live - MarketSmith India

<a href="https://news.google.com/rss/articles/CBMibEFVX3lxTE9hVU1HeHU3VXVKOEdId1c3SjFkS2gzOVAxdVlxZzVrcUFwLV9uR0tKRGpxVXJsS2JNRVl1ZzZ6aWFJd3ctSjE4ZmsyaTFHaFBTTDdMZ2ZDUlJJRzVpZmFBdVVUQ2RBTlFDaW9QdA?oc=5" target="_blank">Gujarat Kidney & Supe…

GKSL — Frequently Asked Questions

What is the current share price of Gujarat Kidney And Super Speciality Limited (GKSL)?

As of 2026-10-24 04:55 IST, Gujarat Kidney And Super Speciality Limited (GKSL) trades at ₹179.46 on NSE. Its 52-week range is ₹99.36 to ₹194.69.

What is the market capitalisation of GKSL?

Gujarat Kidney And Super Speciality Limited (GKSL) has a market capitalisation of ₹1,414.92 Cr on NSE.

What is the P/E ratio of GKSL?

GKSL trades at a trailing price-to-earnings (P/E) ratio of 70.65. The industry average P/E is 35.90. Its price-to-book (P/B) ratio is 4.54.

What is the return on equity (ROE) of GKSL?

GKSL has a return on equity (ROE) of 6.14%. Its return on capital employed (ROCE) is 8.57%.

Is GKSL a good stock to buy?

This page provides a data-driven analysis of Gujarat Kidney And Super Speciality Limited (GKSL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space